Brief introduction of 17739-45-6

When you point to this article, it is believed that you are also very interested in this compound(17739-45-6)Category: pyridazine and due to space limitations, I can only present the most important information.

Category: pyridazine. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: 2-(2-Bromoethoxy)tetrahydro-2H-pyran, is researched, Molecular C7H13BrO2, CAS is 17739-45-6, about New GSH-responsive amphiphilic zinc(II) phthalocyanine micelles as efficient drug carriers for combinatorial cancer therapy. Author is Guo, Shanlei; Gao, Bo; Li, Dongni.

Combination therapies for the treatment of cancer have attracted wide attention. The poor selectivity and biocompatibility of photosensitizers (PS) limit the use of combination therapies in chemotherapy and photodynamic therapy (PDT) for cancer. In this work, the Gender PS (mPEG-b-PLA-S-S-ZnPC), asym. zinc(II) phthalocyanine (ZnPC) and mono-methoxy oxygen-based polyethylene glycol-polylactic acid (mPEG-b-PLA) were designed and synthesized for PDT through disulfide bond (-S-S-). The amphipathic PS could be self-assembled into a micelle in aqueous solution, and paclitaxel (PTX) was encapsulated in the core of the micelle for chemotherapy (PTX/mPEG-b-PLA-S-S-ZnPc). The PTX/mPEG-b-PLA-S-S-ZnPc micelle was spherical with a uniform diameter of about 184 nm. At the first 48 h, the release behaviors of ZnPC and PTX at 10 mmol / L GSH were 30% and 75.2%, resp. These results suggested that GSH-responsive PTX/mPEG-b-PLA-S-S-ZnPc micelle was an active ingredient in combination therapies for cancer.

When you point to this article, it is believed that you are also very interested in this compound(17739-45-6)Category: pyridazine and due to space limitations, I can only present the most important information.

Reference:
Pyridazine – Wikipedia,
Pyridazine | C4H4N2 – PubChem